Drew Moghanaki: Insights on patients over 75 in the CALGB 140503 study

Drew Moghanaki shared the following on X:

“I’ve been thinking a lot about the patients older than 75 who participated in the CALGB 140503 study and were randomized to lobectomy (n=129). Their 90-day mortality rate was over 3%.

Their 90-day mortality rate was over 3%.

”

Source: Drew Moghanaki/X

Dr. Drew Moghanaki, a Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA. He holds the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the same university.

He specializes in treating lung cancer and other thoracic malignancies, focusing on advanced radiation therapy techniques like stereotactic body radiation therapy (SBRT), magnetic resonance-guided radiation therapy (MRgRT), and intensity-modulated radiation therapy (IMRT).